PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
- Conditions
- Healthy Subjects
- Interventions
- Biological: Adalimumab-USBiological: PF-06410293Biological: Adalimumab-EU
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 362
- Registration Number
- NCT02237729
- Locations
- πΊπΈ
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States
πΊπΈPrism Research, LLC, Saint Paul, Minnesota, United States
πΊπΈDe La Pedraja Radiology Associates, Coral Gables, Florida, United States
A Study To Understand How The Body Reacts To A Low Dose Of PF-06427878 When Given In A Vein To Healthy, Adult, Males
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT02237742
- Locations
- π¬π§
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 163
- Registration Number
- NCT02228382
- Locations
- πΊπΈ
University of Miami Hospital & Clinics, Miami, Florida, United States
πΊπΈSiteman Cancer Center - West County, Creve Coeur, Missouri, United States
πΊπΈSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
- Conditions
- Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2019-01-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT02226172
- Locations
- πΊπΈ
Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York, New York, United States
πΊπΈWeill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States
πΊπΈWeill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT02224664
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈCarolina Phase I Research, LLC, Raleigh, North Carolina, United States
πΊπΈMassachusetts General Hospital -- FOR DRUG SHIPMENT ONLY, Boston, Massachusetts, United States
Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT02224651
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT02222922
- Locations
- πΊπΈ
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States
πΊπΈStanford Cancer Center, Stanford, California, United States
πΊπΈStanford Hospital and Clinics, Stanford, California, United States
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: InfliximabBiological: PF-06438179
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 650
- Registration Number
- NCT02222493
- Locations
- πΉπ³
Rabta Hospital, Tunis, Tunisia
πΊπΈRegional Medical Clinic, Rapid City, South Dakota, United States
π¬πͺLTD Tbilisi Central Hospital, Tbilisi, Georgia
Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT02222441
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51
- Registration Number
- NCT02219048
- Locations
- πΊπΈ
Clinical Research Center of Alabama, Birmingham, Alabama, United States
πΊπΈPulmonary Associates, Pa, Phoenix, Arizona, United States
πΊπΈLittle Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, United States